Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection
European clinicians will have a new weapon to combat cervical cancer with the introduction of Abbott Molecular's real-time polymerase chain reaction (PCR) based diagnostic test for human papillomavirus (HPV). The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer.
Read more ...
Genzyme and Isis Begin New Clinical Trials of Mipomersen
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) have begun two new studies of mipomersen, a novel lipid-lowering drug in late-stage development, and a third is currently screening patients. These three trials will provide additional data on mipomersen in high-risk patient populations.
Read more ...
GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.
GlaxoSmithKline plc [LSE/NYSE: GSK] has announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. [Nasdaq: GNLB].
Read more ...
U.S. Patent and Trademark Office Accepts Pfizer's Reissue Application on Lipitor
Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" accepting the company's application to correct the technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.
Read more ...
Novo Nordisk and VLST Corporation announce collaboration agreement
Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, have entered into an exclusive, worldwide collaboration agreement to develop therapeutic targets utilising VLST's technology platform in the fields of autoimmune and inflammatory disorders.
Read more ...
GlaxoSmithKline to cease providing corporate political contributions
GlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future.
Read more ...
Glivec shows significant benefit for gastrointestinal stromal tumor (GIST) patients
Glivec® (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).
Read more ...